Biofabrication is gaining interest as a mean to produce nanostructured functional materials because of its operational versatility and full scalability. Materials based on proteins are especially appealing as protein structure and functionality are adaptable by genetic engineering. Furthermore, strategies and tools for protein production have been steadily developed and refined for more than 30 years. However, protein conformation and therefore activity might be sensitive to production conditions. We have explored here whether the downstream strategy influences structure and biological activities, in vitro and in vivo, of a self-assembling, CD44-targeted proteinonly nanoparticle produced in Escherichia coli. This has been done by the comparative analysis of particles built of soluble protein species or protein versions obtained by in vitro protein extraction from inclusion bodies, through mild, non-denaturing procedures.
Introduction
Protein materials are gaining interest in diverse arms of nanomedicine, especially in tissue engineering and drug delivery. This is because of the functional and structural versatility and tunability of proteins, the possibility to generate new functions through designing non-natural amino acid sequences, the unique merging between structure and function and the establishment of engineering principles to control protein selfassembling at the nanoscale 1, 2 . Ribbons, tapes, fibres, hydrogels, films and particles result from the organized cross-interaction between discrete building blocks 3 . These fall into two main categories, namely peptides and multidomain proteins. While short peptides are synthesized chemically, full-length proteins and many long peptides need to be produced by biological fabrication in recombinant cells. Since the methodological principles supporting recombinant protein production were already established in the late 70's, we have accumulated experience, tools and know-how for almost 4 decades about the functioning and physiology of cell factories, especially Escherichia coli. The first insulin version approved for use was produced in E. coli, and an important fraction of the protein drugs currently in the market are also produced in this bacterial species 4 .
Being the physiology of protein production more complex than formerly believed, genetics, genomics, proteomics, systems biotechnology and metabolic engineering are increasingly providing progresses and optimization of bacterial protein production, aimed to improve yield and functional quality of target products 5, 6 . While some recombinant polypeptides are straightforward obtained as soluble versions, many other protein species, in particular when having a non-bacterial origin or upon extensive engineering, result in insoluble aggregates named inclusion bodies (IBs) 7 . Although in the last decade the biological properties of IBs have been deeply dissected at molecular and physiological levels 8 , their formation is, in most cases, unavoidable 9 .
For use as soluble species, for instance as drugs, target proteins that are produced as IBs need to be denatured and refolded in vitro by the application and progressive removal of solubilizing agents such as urea or guanidinium 10, 11 . Being this approach convenient regarding some aspects (as these aggregates are a cost-effective and relatively pure source of protein), protein refolding from IBs involves complex protocols that need tedious development, the use of toxic chaotropic agents and a case-per-case adaptation.
More recently, and based on the realization that bacterial IBs contain significant fractions of properly folded protein species 12 , non-denaturing protocols for direct protein extraction have been developed 13 . They are based on mild treatment with detergents or organic solvents that promote the release of soluble or quasi-soluble protein. Such releasable protein fraction is probably attached to core amyloid fibres that form the IB skeleton by specific stereospecific interactions 14, 15 . Being highly promising in the case of polypeptides intended for conventional uses (for instance enzymes or hormones), these methods have been never tested in the fabrication of more complex protein structures such as smart protein nanoparticles, resulting from protein selfassembling and intended, for instance, as vehicles for targeted drug delivery upon systemic administration. We have here explored the non-denaturing extraction of two tumor-homing protein nanoparticles (A5G27-GFP-H6 and FNI/II/V-GFP-H6) in which CD44-targeted peptides are displayed on GFP-based, self-assembling building blocks 16 . As these subunits are partially produced as soluble species and also as IBs, it has been possible to comparatively explore nanoparticle architecture, cell internalization and in vivo whole-body biodistribution when the oligomers resulted from either IBextracted or soluble building blocks. Our data demonstrate that the choice of the downstream procedure is not irrelevant regarding the final performance of the materials but that instead compromises their functional quality and biological effectiveness at both cell and systems levels.
Material and methods

Protein design and biological production
The chimeric proteins A5G27-GFP-H6 and FNI/II/V-GFP-H6 contain the CD44-binding peptides A5G27 (fragment 2975-2987 from laminin α5 chain protein, RLVSYNGIIFFLK) and FNI/II/V (fragment 1923-1991 from fibronectin protein, WQPPRARITGYIIKYEKPGSPPREVVPRPRPGVTEATITGLEPGTEYTIYVIALKNN QKSEPLIGRKKT) respectively, displayed at the amino terminus of a His-tagged enhanced GFP ( Figure 1A ). These proteins act as building blocks of self-assembling protein nanoparticles, intended as carriers for targeted drug delivery, that are internalized by CD44 + cells by receptor specific interactions and subsequent receptormediated endocytosis 16 . While the cationic nature of the N-terminal peptides (milder for A527) promotes protein self-assembling, in combination with the H6 tail, they also act as CD44 ligands with distinguishable efficiencies 16 . The encoding genes were harboured in the plasmid pET22b, that was transformed into Escherichia coli BL21 (F -omp ThsdSB(rB -mB -) gal dcmDE3, Novagen). Protein production was induced by the addition of 1 mM IPTG in bacterial cultures growing in LB medium plus ampicillin (100 µg/mL) at 16°C and under stirring at 250 rpm. Upon overnight culture, bacterial cells were centrifuged for 15 min (5,000 g at 4°C) for harvesting.The medium-scale production of recombinant proteins was partially performed by the ICTS "NANBIOSIS", more specifically by the Protein Production Platform of CIBER in Bioengineering, Biomaterials & Nanomedicne (CIBER-BBN)/ IBB, at the UAB (SepBioEs, http://http://www.nanbiosis.es/unit/u1-protein-production-platform-ppp/).Under these production conditions, soluble and aggregated protein species were observed in both cases.
Protein purification and preliminary characterization
Pellets of bacterial cells were resuspended in Tris buffer (20 mM Tris, pH 8.0, 500 mM NaCl, 10 mM imidazole) in the presence of protease inhibitors (Complete EDTA-Free, Roche, Basel, Switzerland). Cells were disrupted at 1,200 psi in a French press (Thermo FA-078A) and the lysate was centrifuged at 15,000 g for 45 min. The insoluble fraction was kept apart for the purification of IBs and further protein extraction. The soluble fraction (named SN1) was filtered through 0.22 µm filter to be later submitted to His-tag affinity chromatography in HiTrap Chelating HP 1 mL columns (GE Healthcare, Piscataway, NJ, USA) with an ÄKTA purifier FPLC System (GE Healthcare). Elution was achieved by a linear gradient of 20 mMTris, pH 8.0, 500 mM NaCl, and 500 mM imidazole.
For protein extraction from IBs a previously published protocol 17 was slightly adapted.
In summary, the insoluble cell fraction obtained from lysate centrifugation was resuspended twice with MilliQ H2O and centrifuged at 15.000 g for 30 min at 4 ºC; supernatants were named SN2 and SN3 respectively. The pellet was resuspended in Tris buffer (40 mM Tris HCl with 0.2 % N-lauroyl sarcosine, pH 8.0) with a ratio of 40 mL buffer/g pellet in the presence of protease inhibitor (Complete EDTA-Free, Roche, Basel, Switzerland) and agitated for 24 h at room temperature. Sample was centrifuged at 15,000 g for 45 min at 4 ºC and supernatant with resolubilized protein was filtrated before being purified by His-tag affinity chromatography using HiTrap Chelating HP 1 mL columns (GE Healthcare) with an ÄKTA purifier FPLC System (GE Healthcare).
Elution was achieved by a linear gradient of 20 mMTris HCl, pH 8.0, 500 mM NaCl, 500 mM imidazole and 0.1 % N-lauroyl sarcosine. For purification of FNI/II/V-GFP-H6, TrisHCl buffer was substituted for 166 mM NaHCO3 to avoid protein precipitation. Proteins were finally dialyzed overnight at 4 ºC against working buffer (166 mM NaHCO3 at pH 7.4). For consistence, only proteins released from the ÄKTA purifier in the last major peak (those showing higher affinity for the matrix), were selected for further analyses in all cases (for both soluble and IB-extracted protein versions).
Eluted protein-containing fractions were analyzed by both SDS electrophoresis/Coomassie Brilliant Blue staining and Western blotting using an antiHis monoclonal antibody (Santa Cruz Biotechnology Inc., Heidelberg, Germany).
Protein concentration was determined by Bradford's assay as described elsewhere 18 .
Field Emission Scanning Electron Microscopy (FESEM) and Dynamic Light
Scattering (DLS)
As a qualitative approach, purified proteins were diluted to 200 μg/mL working buffer, and 10 µL of each one were deposited onto silicon wafers (Ted Pella Inc., Redding, CA, USA) for 2 min, the excess of liquid was adsorbed with Whatman paper and air dried.
Ultrastructural morphometry samples (size and shape) was then observed at a nearly native state without coating with a high resolution in-lens secondary electron detector through a field emission scanning electron microscope Zeiss Merlin (Oberkochen,
Germany) operating at 0.8 kV. As a quantitative approach, volume size distribution of nanoparticles was determined by DLS at 633 nm (in a Zetasizer Nano ZS, Malvern Instruments Limited, Malvern, UK) at a protein concentration of 1 mg/mL. DLS measurements to assess protein stability in physiologic medium were performed after 2 h incubation of A5G27-GFP-H6 nanoparticles at 1.5 µM (45 µg/mL) in OptiPro ® medium. Zeta-potential of these materials were determined in the same device once diluted in working buffer at 0.6 mg/mL final protein concentration.
Size Exclusion Chromatography (SEC)
The molecular weight and Stroke's diameter distribution of protein nanoparticles were determined by SEC after injection of 100 μL-samples with working buffer at 0.5 mL/min, in a previously calibrated Superdex 200 10/300 GL (Tricorn) column (GE Healthcare).
Fluorescence Spectroscopy
Different fluorescence emissions were measured at 25 ºC in a Variant Cary Eclipse Fluorescence Spectrophotometer (Agilent Technologies), using a 1-cm pathlenght quartz cuvette. Green fluorescence emission was determined for 1-mg/ml protein samples in working buffer at a detection wavelength of 510 nm and an excitation wavelength of 450 nm. The variation in the tertiary structure of A5G27-GFP-H6
(containing a unique tryptophan residue) was analysed by intrinsic Trp-fluorescence for 0.5 mg/ml protein samples. Temperature-dependent Trp emission fluorescence was recorded at 330 nm every 0.5 ºC from 20 to 100 ºC using an excitation wavelength of 280 nm. Scans were recorded along the 290-400 nm range at given temperatures after 8 min of temperature equilibration, and 10 scans were averaged.
Circular Dichroism
Far-UV circular dichroism (CD) was measured at 25ºC in a Jasco J-715 spectropolarimeter to assess secondary structure differences. Proteins were analysed at 10 µM (0.3 µg/mL) in working buffer with 1 mm pathlength quartz cuvette. CD spectra were obtained over the wavelength range of 200-250 nm at a scan rate of 50 nm/min, a response of 2 s, and a bandwidth of 1 nm. Ten scans were accumulated. To assess conformational differences, spectra were superimposed by applying a 1.5 multiplication factor.
Protein modelling
The A5G27-GFP-H6 monomer was modelled by homology using Modeler 9v13 19 and the following templates: mouse laminin alpha2 chain lg4-5 domain pair (pdb entry 1okq, residues A2789 to A2802, 21.4 % identity, 71.4 % similarity) 20 and mouse laminin alpha1 chain, domains lg4-5 (pdb entry 2jd4, residues A2905 to A2918, 28.6 % identity, 50 % similarity) 21 for A5G27 residues 1 to 14; residues 43 to 49 of the globular domain of Gallus gallus histone H5 (pdb entry 1hst 22 for residues 15 to 21 in the connecting segment (85 % identity); and pdb entry 1qyo for GFP 23 (residues 21 to 256, 98 % identity). The histidine tail was modelled by Modeller's automodel function (residues 257 to 263), with 500 models generated and sorted by their DOPE score 24 . The 20 models with best DOPE score were analyzed with the Electrostatic-Desolvation-Profile method 25 , in order to predict putative protein-protein binding patches.
Total carbohydrate and lipid analysis
A phenol-sulphuric acid assay was performed to determine the total amount of carbohydrates present in protein samples. For that, 225 µg of protein were lyophilized and 150 µL of 18 M sulphuric acid were added and immediately, 30 µL of 5 % phenol.
Samples were incubated at 90 ºC for 5 min, cooled to room temperature and optical density was measured at 490 nm. A glucose standard was prepared with a range from 0 to 400 ng.
The total amount of lipids in the samples was analyzed by the sulfo-phospho vanillin colorimetric method. In short, 1 mg of each sample was lyophilized and dissolved in 200 µL chloroform. After chloroform was evaporated, 100 μL of water were added.
Samples were transferred to glass tubes and 2 mL of 18 M sulphuric acid were added.
Then, samples were incubated for 10 min in a boiling water bath and subsequently cooled down in water bath at RT. After treatment with 5 mL phosphoric acid-vanillin reagent (85 % (v/v) phosphoric acid and 1.2 g/L vanillin (Sigma Aldrich, Steinheim, Germany)), the samples were warmed at 37 ºC for 15 min and cooled for 10 min in water bath at RT. Absorbance at 530 nm was measured. For the standard curve, a range of 10-100 μg triolein was used.
Cell line and cell manipulation
Human breast cancer cell line MDA-MB-231 was obtained from the ATCC (Rockville, MD, USA). MDA-MB-231 used for flow-cytometry and confocal imaging were maintained in RPMI 1640 medium supplemented with 10 % FBS and 6 mM GlutaMAX 
Analysis of protein stability
Protein stability was analyzed in triplicate at 115 µg/ml final concentration in reconstituted human plasma (Sigma-Aldrich, Ref: S225-5 ml), after 30 min, 1 h, 2 h, 4 h and 24 h of incubation at 37 ºC, under mild agitation. Protein green fluorescence was determined as described above. Sample at 24 h was centrifuged and fluorescence of the soluble fractions was re-analyzed to discard protein aggregation. to avoid the conventional, complex and product-specific denaturation-based refolding protocols that rely on the multi-step use of chaotropic agents 10, 11 . Upon French press cell-disruption, extraction of GFP from GFP IBs maintains the native specific fluorescence 28 , thus stressing the mildness of the procedure. This novel category of separation methods is based on the recognition of functional proteins occurring in bacterial IBs 29, 30 , that are architectonically combined with amyloidal networks [31] [32] [33] [34] . Therefore, we concluded that as suggested by morphological data (Figure 3 A, B) and fluorescence recording (Figure 3 E) , the discrimination of biological behaviour between A5G27-GFP-H6 sol and A5G27-GFP-H6 rIB might be derived from conformational variability in the nanoparticles as derived from distinct separation methods downstream the biological fabrication. Importantly, the mild extraction of monomeric GFP from IBs using the same protocol than in the present study does not affect specific fluorescence 28 . Therefore, the differences in the specific fluorescence observed here between the two A5G27-GFP-H6 particle versions must be linked to the ability shown by this protein to oligomerize as nanoparticles (in which monomers probably encounter distinguishable molecular environments).
Orthotopic mammary fat pad mouse models
The hypothesis of conformational variability between A5G27-GFP-H6 sol and rIB nanoparticles was supported by secondary and tertiary structure analyses ( Figure 7 ).
The far-UV CD spectra revealed changes in ellipticity at around 210 nm, revealing that β-sheet content is somewhat higher in rIB oligomers than in those obtained from the sol version ( Figure 7A ). In addition, the rIB spectrum had to be multiplied by a 1.5 factor in order to be superimposed to the sol spectrum, which reflects that rIB nanoparticles are less soluble than sol nanoparticles, and, in turn, concurs with a β-sheet-rich associating conformation. Differences on tertiary structure were determined by measuring tryptophan intrinsic fluorescence at different temperatures. Temperature-dependent fluorescence intensity at 330 nm presents different decreasing slope for each nanoparticle, with that for rIB showing a particular transition between 70 and 80 ºC ( Figure 7B ).In order to delve into this heat-induced different behaviour, Trp emission spectra were recorded at different temperatures ( Figure 7C-D) . Although intensity decreases with temperature in both cases (as already shown in Figure 7B ), it is noteworthy that the maximum of the sol variant spectrum suffers a slight redshift (from 331 nm to 335 nm) upon increasing temperature, whereas the rIB variant behaves the opposite, blueshifting from 329 nm to 310 nm; in addition, the maximum of the spectra remains the same from 20 to 60 ºC and suddenly blueshifts between 60-80º C, in consonance with the mentioned particular transition in the denaturation plot followed by intensity at 330 nm ( Figure 7B ). Therefore, it can be concluded that whereas the sol variant partially unfolds or initiates an unfolding process (albeit not reaching the fully unfolded state, characterized by a maximum at 355 nm), the rIB variant packs such that Trp residues are buried within the nanoparticle. Moreover, the maxima of the rIB initial spectra (20ºC) is 2 nm blueshifted with respect to the one for the sol variant and this effect, although slight, is also observed at the temperature closest to physiologic conditions (at 40ºC the difference among both variants is 3 nm), suggesting that, in vivo, rIB nanoparticles may display a more compact conformation than those obtained from the soluble variant.
In vivo biodistribution of nanoparticles. To investigate any potential variation in the whole-body biodistribution maps of A5G27-GFP-H6 derived nanoparticles, we administered these materials to CD44 
Discussion
The microbial synthesis of nanostructured materials is gaining interest versus the most conventional chemical production because of the flexibility, scalability and cost effectiveness of cell factories, and due to the inherent, environmentally friendly nature of biological fabrication [38] [39] [40] . Different types of materials, including proteins 3 , metals 41 and polymers 42, 43 are produced in microbial cells, among which many of them are intended for biomedical applications 44 . The adaptation and implementation of microorganisms alternative to gram negative bacteria is expanding the diversity of products resulting from biological fabrication, especially concerning difficult-to-express proteins [45] [46] [47] [48] [49] . Being E. coli together with its expression vectors an extremely versatile toolbox in bioproduction, the recent development and application of endotoxin-free strains of this species 50, 51 paves the road for a reassessment of this cell factory in BioPharma. Among nanoscale microbial products, those based on proteins exhibit particular properties associated to the unique integration of structure and function,
properties that can be tailored and re-designed by plain genetic engineering. In this regard, the emergence of principles to rationally engineer protein self-assembling [52] [53] [54] [55] [56] [57] [58] allows the production, in recombinant cells, of a spectrum of protein materials such as particles, fibres, films, ribbons and hydrogels At the systems level, A5G27-GFP-H6 rIB and A5G27-GFP-H6 sol nanoparticles target the tumor tissue similarly, but their side accumulation in non-target organs is clearly different (Figure 8 A) . Regarding renal filtration, the major route for excretion of small materials, larger A5G27-GFP-H6 rIB nanoparticles showed low retention in kidney compared to A5G27-GFP-H6 sol counterparts. Larger nanoparticles are able to escape glomerular filtration and hold a longer plasma half-life, but are also prone for the uptake by the organs of the reticuloendothelial system such as the liver and lung 67, 68 , as it happens here with the A5G27-GFP-H6 rIB version. In addition, the higher accumulation of this construct in lung may be also due to initial clustering of nanoparticles and their first-pass retention in lung capillaries after systemic administration. The highest prevalence of A5G27-GFP-H6 rIB in the liver might be also enhanced by enlarged exposure of protein-protein interaction-prone regions 69, 70 ( Figure 
